Efficacy and safety of endoscopic resection for small submucosal tumors originating from the muscularis propria layer in the gastric fundus.


Journal

Surgical endoscopy
ISSN: 1432-2218
Titre abrégé: Surg Endosc
Pays: Germany
ID NLM: 8806653

Informations de publication

Date de publication:
08 2019
Historique:
received: 01 05 2018
accepted: 15 10 2018
pubmed: 28 11 2018
medline: 30 4 2020
entrez: 28 11 2018
Statut: ppublish

Résumé

Gastric small submucosal tumors (SMTs) are becoming increasingly common. However, the fundus of stomach is regarded as a difficult area for endoscopic resection (ER). In this study, we investigated the efficacy, safety, and long-term outcomes of ER for small SMTs of the gastric fundus in a large series of patients, research that was previously lacking. 537 consecutive patients with SMTs no more than 20 mm in diameter, occurring in the gastric fundus and originating from the muscularis propria layer, which were treated with endoscopic submucosal excavation or endoscopic full-thickness resection (EFTR) were included in this retrospective study at Zhongshan Hospital of Fudan University from January 2013 to September 2016. Clinicopathological, endoscopic, and follow-up data were collected and analyzed. En bloc resection was achieved in 100% of patients, and complete resection was achieved for 530 (98.7%) lesions. Although the total rate of complications was 9.3%, few serious adverse events occurred in only three (0.6%) patients, including major pneumoperitoneum, major hydrothorax, and bleeding. Unlike lager tumor sizes and longer procedure times, endoscopist experience had a positive impact on decreasing the likelihood of complications. Based on statistical analysis, tumors with greater size near the cardia, which were treated by EFTR, were the significant contributors to longer operative times. A median follow-up of 32 months was available, and all patients were free from local recurrence or distant metastasis during the study period. Although the gastric fundus presents technical difficulties, ER is effective for the resection of small gastric SMTs with a high complete resection rate and rare serious adverse events.

Sections du résumé

BACKGROUND
Gastric small submucosal tumors (SMTs) are becoming increasingly common. However, the fundus of stomach is regarded as a difficult area for endoscopic resection (ER). In this study, we investigated the efficacy, safety, and long-term outcomes of ER for small SMTs of the gastric fundus in a large series of patients, research that was previously lacking.
METHODS
537 consecutive patients with SMTs no more than 20 mm in diameter, occurring in the gastric fundus and originating from the muscularis propria layer, which were treated with endoscopic submucosal excavation or endoscopic full-thickness resection (EFTR) were included in this retrospective study at Zhongshan Hospital of Fudan University from January 2013 to September 2016. Clinicopathological, endoscopic, and follow-up data were collected and analyzed.
RESULTS
En bloc resection was achieved in 100% of patients, and complete resection was achieved for 530 (98.7%) lesions. Although the total rate of complications was 9.3%, few serious adverse events occurred in only three (0.6%) patients, including major pneumoperitoneum, major hydrothorax, and bleeding. Unlike lager tumor sizes and longer procedure times, endoscopist experience had a positive impact on decreasing the likelihood of complications. Based on statistical analysis, tumors with greater size near the cardia, which were treated by EFTR, were the significant contributors to longer operative times. A median follow-up of 32 months was available, and all patients were free from local recurrence or distant metastasis during the study period.
CONCLUSIONS
Although the gastric fundus presents technical difficulties, ER is effective for the resection of small gastric SMTs with a high complete resection rate and rare serious adverse events.

Identifiants

pubmed: 30478693
doi: 10.1007/s00464-018-6549-6
pii: 10.1007/s00464-018-6549-6
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2553-2561

Références

World J Gastroenterol. 2014 Sep 7;20(33):11800-7
pubmed: 25206285
Gastrointest Endosc. 2017 May;85(5):956-962
pubmed: 27663715
Gastrointest Endosc. 2016 Feb;83(2):318-26
pubmed: 26227928
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
pubmed: 26808342
Gastroenterology. 2006 Jun;130(7):2217-28
pubmed: 16762644
J Natl Compr Canc Netw. 2016 Jun;14(6):758-86
pubmed: 27283169
J Gastrointestin Liver Dis. 2009 Jun;18(2):177-80
pubmed: 19565047
J Dig Dis. 2015 Nov;16(11):642-8
pubmed: 26431118
Ann Surg. 2017 Feb;265(2):363-369
pubmed: 28059965
Eur J Gastroenterol Hepatol. 2012 Oct;24(10):1135-44
pubmed: 22797706
BMJ Case Rep. 2014 Oct 29;2014:
pubmed: 25355752
Curr Gastroenterol Rep. 2011 Dec;13(6):532-9
pubmed: 21931997
Chin J Cancer. 2011 May;30(5):303-14
pubmed: 21527063
Exp Ther Med. 2013 Aug;6(2):391-395
pubmed: 24137195
Surg Endosc. 2016 Nov;30(11):5099-5107
pubmed: 27005293
Surg Endosc. 2013 Sep;27(9):3271-9
pubmed: 23519491
United European Gastroenterol J. 2016 Apr;4(2):250-6
pubmed: 27087954
Surg Endosc. 2016 Sep;30(9):3994-4000
pubmed: 26701702
Hum Pathol. 2008 Oct;39(10):1411-9
pubmed: 18774375
World J Gastrointest Endosc. 2011 May 16;3(5):86-94
pubmed: 21772939
Gastrointest Endosc. 2017 Jun;85(6):1117-1132
pubmed: 28385194
J Gastroenterol Hepatol. 2017 Oct;32(10):1693-1697
pubmed: 28220962
Surg Endosc. 2017 Nov;31(11):4522-4531
pubmed: 28374257
Gastrointest Endosc. 2017 Aug;86(2):349-357.e2
pubmed: 27899322
Gastrointest Endosc. 2012 Jun;75(6):1153-8
pubmed: 22459663
Gastric Cancer. 2012 Jan;15(1):83-90
pubmed: 21761134
World J Gastroenterol. 2007 Apr 14;13(14):2077-82
pubmed: 17465451
Surg Endosc. 2015 Dec;29(12):3588-93
pubmed: 25894443
Endoscopy. 2005 Jul;37(7):630-4
pubmed: 16010607
Endoscopy. 2013;45(5):329-34
pubmed: 23468195
Surg Endosc. 2011 Sep;25(9):2926-31
pubmed: 21424195
World J Gastroenterol. 2011 Apr 7;17(13):1766-71
pubmed: 21483639

Auteurs

Bing Li (B)

Endoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Endoscopy Research Institute of Fudan University, Shanghai, 200032, China.

Tao Chen (T)

Endoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Endoscopy Research Institute of Fudan University, Shanghai, 200032, China.

Zhi-Peng Qi (ZP)

Endoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Endoscopy Research Institute of Fudan University, Shanghai, 200032, China.

Li-Qing Yao (LQ)

Endoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Endoscopy Research Institute of Fudan University, Shanghai, 200032, China.

Mei-Dong Xu (MD)

Endoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Endoscopy Research Institute of Fudan University, Shanghai, 200032, China.

Qiang Shi (Q)

Endoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Endoscopy Research Institute of Fudan University, Shanghai, 200032, China.

Shi-Lun Cai (SL)

Endoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Endoscopy Research Institute of Fudan University, Shanghai, 200032, China.

Di Sun (D)

Endoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 200032, China.
Endoscopy Research Institute of Fudan University, Shanghai, 200032, China.

Ping-Hong Zhou (PH)

Endoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 200032, China. zhoupinghongzs@yahoo.com.
Endoscopy Research Institute of Fudan University, Shanghai, 200032, China. zhoupinghongzs@yahoo.com.

Yun-Shi Zhong (YS)

Endoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 200032, China. zhongyunshi@yahoo.com.
Endoscopy Research Institute of Fudan University, Shanghai, 200032, China. zhongyunshi@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH